Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PRCP | P42785 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8112308 | 0.94 | SLC6A2 (0.44) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL4441268 | 0.90 | SLC6A2 (0.43) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL3786109 | 0.81 | SLC6A2 (0.38) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL3933873 | 0.80 | LMNA (0.40) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL8351844 | 0.80 | SLC6A2 (0.37) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL13229259 | 0.79 | OPRM1 (0.51) | MEN1KMT2APRCPSIGMAR1OPRM1 | |
| SCHEMBL2987797 | 0.78 | SLC6A2 (0.37) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL3934675 | 0.78 | CYP2C9 (0.36) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| Ethylene SCHEMBL11087552 | 0.78 | LMNA (0.38) | SLC6A2MEN1KMT2APRCPSIGMAR1 | |
| SCHEMBL24525763 | 0.76 | MEN1 (0.42) | SLC6A2MEN1KMT2APRCPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10757937-B2 | Sulfonamides that activate ABA receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170231224-A1 | SULFONAMIDES THAT ACTIVATE ABA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-08-17 | — | — | US | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016069637-A1 | SULFONAMIDES THAT ACTIVATE ABA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-8877975-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| CN-101394847-A | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC (US) | 2009-03-25 | — | — | CN | disclosed |
| EP-1976513-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sepracor, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
| US-5223530-A | Selective high-affinity ligands for treatment of psychological disorders, side effect reduction | SRI, INTERNATIONAL (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0495084-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002481-A1 | ARYLCYCLOALKANEPOLYALKYLAMINES | SRI INTERNATIONAL (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5086054-A | Selective high-affinity ligands to sigma boding sites, administering, amipsychotic, antiarrhythmia, antiischemic agents anticonvulsants, reduced side effects | SRI INTERNATIONAL (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885MEN1 4234/4885KMT2A 755/4885 |
| US-10757937-B2 | Sulfonamides that activate ABA receptors | STS, NAAA, ARSA | SLC6A2 3786/4885MEN1 4884/4885KMT2A 2050/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885MEN1 4234/4885KMT2A 755/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885MEN1 4234/4885KMT2A 755/4885 |
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | SLC6A2 256/4885MEN1 368/4885KMT2A 3959/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885MEN1 4234/4885KMT2A 755/4885 |
| US-20170231224-A1 | SULFONAMIDES THAT ACTIVATE ABA RECEPTORS | STS, NAAA, ARSA | SLC6A2 3786/4885MEN1 4884/4885KMT2A 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.